CRISPR Therapeutics (CRSP) is trading higher today as sentiment improves around the company’s lead commercial product, CASGEVY, and the next set of measurable commercialization and regulatory catalysts. Recent company communications have reiterated that Vertex is expected to initiate global regulatory submissions for CASGEVY in children ages 5–11 in the first half of 2026, which investors often treat as an important de-risking step for expanding the addressable market. (ir.crisprtx.com)

CASGEVY is the company’s first major revenue driver, and CRISPR Therapeutics has pointed to continued growth in treated patients and broader reimbursement access across key markets. In its February 12, 2026 update, CRISPR Therapeutics reported CASGEVY revenue of $54 million in Q4 2025 and $116 million for full-year 2025, with 64 patients receiving infusions during 2025 and 147 initiating the treatment process with first cell collection. (ir.crisprtx.com)

Beyond quarterly commercialization updates for CASGEVY, CRISPR Therapeutics has laid out multiple milestones that can influence expectations through 2026, including updates from CTX310 in the second half of 2026, an Lp(a) program update expected in 2026, and top-line Phase 2 data from CTX611 in the second half of 2026. The company has also signaled plans to initiate additional clinical trials in 2026 (including CTX340 in the first half and CTX460 in mid-2026), which can contribute to periodic risk-on buying when the broader biotech tape is constructive. (ir.crisprtx.com)

Investors will likely focus on (1) quarter-to-quarter progress on patient starts and infusions for CASGEVY, (2) confirmation of timing for pediatric submissions (ages 5–11) and any details on review pace, and (3) clinical updates later in 2026 across CRISPR Therapeutics’ in vivo liver editing and siRNA programs. A separate near-term volatility catalyst is the company’s next earnings date window, which market calendars currently estimate for early May 2026. (marketbeat.com)